High Quality Affordable Reaction Vessels
Asynt has formed a partnership with Asahi Glassplant (AG!) to supply their range of high performance reaction vessels alongside, and incorporated with, its popular ReactoMate Controlled Lab Reactors.
Having visited the AG! production facility in Japan, Asynt Managing Director (Martyn Fordham commented: “I was greatly impressed by the AG! glassblowing capabilities which is technically beyond what I have witnessed anywhere in the last 30 years”. He added: “At Asynt our aim is always to offer the highest specification and best performing products, so consequently the AG! Glass reaction vessels fit perfectly in our portfolio. I believe that the wider chemistry community will benefit considerably from the capabilities of these high specification vessels compared to standard jacketed reactor vessels.”
By using resized glass, AG! can produce reaction vessels with a unique thinner inner jacket wall that increases heat transfer rates but without compromising on the strength or safety aspects of the vessel. A proprietary AG! “ring baffle” fluid jacket design option ensures that the fluid path in reactor vessels is even and removes the risk of hot spots. More importantly, when combined with the thinner reactor jacket, this innovation gives a significant improvement in heating and cooling performance. All AG! reaction vessels include an easily removable zero dead space drain valve assembly even on smaller vessels. As an option, high pressure AG! reactor vessels with performance up to 12 bar pressure are available.
The addition of the AG! reactor vessel range extends the scale of reactors available from Asynt up to 160 L, or up to 60 L with an insulating vacuum jacket.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.